revlimid 25 mg
neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 25 mg - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.
revlimid 5 mg
neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 5 mg - lenalidomide - multiple myeloma (mm) revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.
revlimid 5 mg
neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 5 mg - lenalidomide - multiple myeloma (mm) revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.
cetirizine 10mg tablets
apc pharmaceuticals & chemicals (europe) ltd - cetirizine hydrochloride - oral tablet - 10mg
omega 3-acid-ethyl esters 1000mg capsules
glenmark pharmaceuticals europe ltd - eicosapentaenoic acid; docosahexaenoic acid - oral capsule - 460mg ; 380mg
solifenacin 10mg tablets
glenmark pharmaceuticals europe ltd - solifenacin succinate - oral tablet - 10mg
solifenacin 5mg tablets
glenmark pharmaceuticals europe ltd - solifenacin succinate - oral tablet - 5mg
simbrinza
novartis israel ltd - brimonidine tartrate; brinzolamide - eye drops suspension - brimonidine tartrate 2 mg / 1 ml; brinzolamide 10 mg / 1 ml - brinzolamide, combinations - decrease of elevated intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.
mepivacaine hcl 3 % injection
henry schein shvadent (2009 ) ltd - mepivacaine hydrochloride - solution for injection - mepivacaine hydrochloride 30 mg/ml - mepivacaine - mepivacaine - mepivacaine is indicated for production of local anesthesia for dental procedures by infiltration or nerve block in adults and pediatric patients.
alecensa
roche pharmaceuticals (israel) ltd - alectinib as hydrochloride - capsules - alectinib as hydrochloride 150 mg - alectinib is indicated for the treatment of patients with alk positive, locally advanced or metastatic non-small cell lung cancer (nsclc) who progressed on or are intolerant to crizotinibalecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc).